Background. We previously showed that grading can prognosticate the outcome of retroperitoneal liposarcoma (LPS). In the present study, we aimed to explore the impact of pathological stratification using grading on the clinical outcomes of patients with advanced well-differentiated LPS (WDLPS) and dedifferentiated LPS (DDLPS) treated with trabectedin. Patients: We included patients with advanced WDLPS and DDLPS treated with trabectedin at the Fondazione IRCCS Istituto Nazionale dei Tumori between April 2003 and November 2019. Tumors were categorized in WDLPS, low‐grade DDLPS, and high‐grade DDLPS according to the 2020 WHO classification. Patients were divided in two cohorts: Low‐grade (WDLPS/low‐grade DDLPS) and high‐grade (high‐grade DDLPS). Results: A total of 49 patients were included: 17 (35%) in the low‐grade cohort and 32 (65%) in the high‐grade cohort. Response rate was 47% in the low‐grade cohort versus 9.4% in the high‐grade cohort (logistic regression p = 0.006). Median progression‐free survival (PFS) was 13.7 months in the low‐grade cohort and 3.2 months in the high‐grade cohort. Grading was confirmed as an independent predictor of PFS in the Cox proportional‐hazards regression multivariable model (adjusted hazard ratio low‐grade vs. high‐grade: 0.45, 95% confidence interval: 0.22–0.94; adjusted p = 0.035). Conclusions: In this retrospective case series, sensitivity to trabectedin was higher in WDLPS/low‐grade DDLPS than in high‐grade DDLPS. If confirmed in larger series, grading could represent an effective tool to personalize the treatment with trabectedin in patients with advanced LPS.

Impact of pathological stratification on the clinical outcomes of advanced well‐differentiated/dedifferentiated liposarcoma treated with trabectedin

Fumagalli E.;Dei Tos A. P.;
2021

Abstract

Background. We previously showed that grading can prognosticate the outcome of retroperitoneal liposarcoma (LPS). In the present study, we aimed to explore the impact of pathological stratification using grading on the clinical outcomes of patients with advanced well-differentiated LPS (WDLPS) and dedifferentiated LPS (DDLPS) treated with trabectedin. Patients: We included patients with advanced WDLPS and DDLPS treated with trabectedin at the Fondazione IRCCS Istituto Nazionale dei Tumori between April 2003 and November 2019. Tumors were categorized in WDLPS, low‐grade DDLPS, and high‐grade DDLPS according to the 2020 WHO classification. Patients were divided in two cohorts: Low‐grade (WDLPS/low‐grade DDLPS) and high‐grade (high‐grade DDLPS). Results: A total of 49 patients were included: 17 (35%) in the low‐grade cohort and 32 (65%) in the high‐grade cohort. Response rate was 47% in the low‐grade cohort versus 9.4% in the high‐grade cohort (logistic regression p = 0.006). Median progression‐free survival (PFS) was 13.7 months in the low‐grade cohort and 3.2 months in the high‐grade cohort. Grading was confirmed as an independent predictor of PFS in the Cox proportional‐hazards regression multivariable model (adjusted hazard ratio low‐grade vs. high‐grade: 0.45, 95% confidence interval: 0.22–0.94; adjusted p = 0.035). Conclusions: In this retrospective case series, sensitivity to trabectedin was higher in WDLPS/low‐grade DDLPS than in high‐grade DDLPS. If confirmed in larger series, grading could represent an effective tool to personalize the treatment with trabectedin in patients with advanced LPS.
2021
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3387536
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact